Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration

Ethnic Differences in Ischemia/Bleeding Risk Tradeoff During Antiplatelet Therapy After Drug-eluting Stent Implantation

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03338335

Enrollment

16000

Registered

2017-11-09

Start date

2017-03-01

Completion date

2018-10-31

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Dual Antiplatelet Therapy, Percutaneous Coronary Intervention

Brief summary

this study is an individual patient level meta-analysis of randomized clinical trials, to evaluate the influence of ethnicity, to study whether the relative tradeoff between ischemia and bleeding is distinct by ethnicity.

Interventions

DRUGprolonged DAPT

Dual antiplatelet therapy will be prescribed for more than 12 months

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

19 Years to 100 Years

Healthy volunteers

Inclusion criteria

* patients enrolled in previous RCTs related to the duration of dural antiplatelet agent therapy

Design outcomes

Primary

Measure	Time frame	Description
primary ischemic endpoint	2 years	major adverse cardiac events (MACE) defined as the composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis
primary bleeding endpoints	2 years	major bleeding events

Secondary

Measure	Time frame
non-cardiac death	2 years
all-cause death	2 years
any stroke	2 years
any myocardial infarction	2 years
cardiac death	2 years

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026